Urine proteomics defines an immune checkpoint-associated nephritis signature

Immune checkpoint inhibitor (ICI) therapy is a cornerstone treatment for many cancers, but it can induce severe immunotoxicity, including acute interstitial nephritis (AIN). Currently, kidney biopsy is required to differentiate ICI-AIN from other causes of acute kidney injury (AKI). However, this in...

Full description

Bibliographic Details
Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	Cassian Yee, Jamie S Lin, James P Long, Shailbala Singh, Yanlan Dong
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-01-01
Online Access:	https://jitc.bmj.com/content/13/1/e010680.full

Similar Items

Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis
by: Andrea Fava, et al.
Published: (2024-01-01)

NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression
by: Yen-Po Tsao, et al.
Published: (2023-05-01)

NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression
by: Yen-Po Tsao, et al.
Published: (2023-04-01)

Immune Checkpoint Therapy–Induced Lupus Nephritis
by: Imran Humza Hanif, et al.
Published: (2024-05-01)

Defining subgroups of pediatric nephrotic patients with urine proteomics
by: Timothy D. Cummins, et al.
Published: (2025-07-01)

Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab
by: Cassian Yee, et al.
Published: (2020-10-01)

LO-012 The innate immune checkpoint NLRP12 represses IFN signatures and attenuates the progression of lupus nephritis
by: Yen-Po Tsao, et al.
Published: (2023-07-01)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
by: Sandra M Herrmann, et al.
Published: (2023-01-01)

The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
by: Marco Tucci, et al.
Published: (2019-09-01)

Sequential immune-related nephritis and pneumonitis during immune checkpoint inhibitor therapy: a case report
by: Haocheng Zhao, et al.
Published: (2026-05-01)

Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia
by: Sergio Rutella, et al.
Published: (2022-11-01)

Defining the urine proteome in boys with posterior urethral valves: a pilot study
by: Xin Wang, et al.
Published: (2026-05-01)

Clinical significance of urine hepcidin in lupus nephritis
by: TANG Dai-rong, et al.
Published: (2017-01-01)

LP-098 Proteomic analysis of histological lesions in lupus nephritis identifies an inflammatory signature of fibrous crescents
by: Laurence S Magder, et al.
Published: (2023-07-01)

First-in-human use of recombinant IL-7 to potentiate antigen-specific T cell therapy: a single patient case study
by: Linghua Wang, et al.
Published: (2026-04-01)

Steroid Refractory Immune Checkpoint Induced Acute Interstitial Nephritis Salvaged by Mycophenolate Mofetil
by: Prashanth Moku, et al.
Published: (2023-04-01)

1101 Urine complement activation products in lupus nephritis
by: Brad H Rovin, et al.
Published: (2022-12-01)

NeuroLINCS Proteomics: Defining human-derived iPSC proteomes and protein signatures of pluripotency
by: Andrea D. Matlock, et al.
Published: (2023-01-01)

Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma
by: Raquibul Hannan, et al.
Published: (2020-10-01)

Urine proteomic signatures predicting the progression from premalignancy to malignant gastric cancerResearch in context
by: Hua Fan, et al.
Published: (2022-12-01)

Urine Extracellular Vesicles Size Subsets as Lupus Nephritis Biomarkers
by: Itze C. Navarro-Hernandez, et al.
Published: (2024-10-01)

Urine and serum interleukin 35 as potential biomarkers of lupus nephritis
by: Mary Atef Nassif
Published: (2021-10-01)

Combined transcriptomic and proteomic analyses define conserved host signatures during innate immune perturbations in DF-1 chicken fibroblasts
by: Frederic Sorgeloos, et al.
Published: (2026-05-01)

Glycosphingolipid Levels in Urine Extracellular Vesicles Enhance Prediction of Therapeutic Response in Lupus Nephritis
by: Brian Troyer, et al.
Published: (2022-02-01)

Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
by: Caroline Robert, et al.
Published: (2022-01-01)

Aptamer based proteomic pilot study reveals a urine signature indicative of pediatric urinary tract infections.
by: Liang Dong, et al.
Published: (2020-01-01)

Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis
by: Maen Abdelrahim, et al.
Published: (2021-01-01)

Urine Soluble CD163 Is a Promising Biomarker for the Diagnosis and Evaluation of Lupus Nephritis
by: Yun-Ju Huang, et al.
Published: (2022-07-01)

Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
by: Yu Yamamoto, et al.
Published: (2022-03-01)

Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report
by: Kenta Tominaga, et al.
Published: (2023-03-01)

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor
by: Jose Lutzky, et al.
Published: (2017-11-01)

Exploring urine:serum fractional excretion ratios as potential biomarkers for lupus nephritis
by: Samar A. Soliman, et al.
Published: (2022-08-01)

Correction: Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Published: (2022-12-01)

Biopsy-proven acute tubulointerstitial nephritis in patients treated with immune checkpoint inhibitors: a pooled analysis of case reports
by: Pasquale Esposito, et al.
Published: (2023-10-01)

Corrigendum: Urine soluble CD163 is a promising biomarker for the diagnosis and evaluation of lupus nephritis
by: Yun-Ju Huang, et al.
Published: (2022-08-01)

Differentiating the Whole Urine and Urine Supernatant Protein Profiles of Preterm Infants via Urine Proteomics
by: Lulu Zhang, et al.
Published: (2025-01-01)

Immune Signatures of Solid Tumor Patients Treated With Immune Checkpoint Inhibitors: An Observational Study
by: Ling Chen, et al.
Published: (2025-01-01)

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer
by: Nayoung Kim, et al.
Published: (2024-11-01)

Inflammation and B cell activation define a plasma proteome signature predicting tuberculosis in people with HIV
by: Katharina Kusejko, et al.
Published: (2025-10-01)

Immune checkpoint inhibitors induce acute interstitial nephritis in mice with increased urinary MCP1 and PD-1 glomerular expression
by: Laura Martinez Valenzuela, et al.
Published: (2024-05-01)